Selective COX-2 inhibitors: new insights into mechanisms of side effects?
Flier
Suzanne
S
Buhre
Wolfgang
W
D000818:Animals; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D006439:Hemodynamics; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy; D007783:Lactones / Q000009:adverse effects*; D051379:Mice; D009203:Myocardial Infarction / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D015428:Myocardial Reperfusion Injury / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D009281:Naphthalenes / Q000494:pharmacology / Q000627:therapeutic use; D011422:Propionates / Q000494:pharmacology / Q000627:therapeutic use; D017482:Receptors, Thromboxane / Q000819:agonists / Q000037:antagonists & inhibitors; D013450:Sulfones / Q000009:adverse effects*; D016277:Ventricular Function, Left / Q000187:drug effects; D017725:Ventricular Pressure / Q000187:drug effects
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D009281:Naphthalenes; D011422:Propionates; D017482:Receptors, Thromboxane; D013450:Sulfones; C116926:rofecoxib; C501362:terutroban